InNexus Biotechnology CEO Named Business Leader of the Year

BRITISH COLUMBIA, Canada, Nov. 17  /PRNewswire-FirstCall/ -- InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com/), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL) technology, announced today that the Arizona Technology Council, in partnership with the Arizona Department of Commerce and in conjunction with Arizona Governor Janet Napolitano, named Jeff Morhet, Chairman and CEO, as the Ed Denison Business Leader of the Year at the 2008 Governor's Celebration of Innovation Awards event, which was held on 13 November 2008 at the Dodge Theatre in downtown Phoenix, Arizona.

The Ed Denison Business Leader of the Year Award is presented to an individual who contributes to Arizona's technology industry through sustained growth of their business or company. To be nominated for and receive this award, an individual must be in a leadership position employed by an Arizona-based business or division of a corporation operating in Arizona, and must have resided in Arizona for at least five years. Leadership qualities such as entrepreneurship, community involvement, and management expertise are considered.

"I'm humbled and honored to be recognized by the community and receive this year's Ed Denison Business Leader of the Year Award," said Morhet.  "I am thankful for the support of my family, peers and the InNexus team, who have made this award possible.  Congratulations also to the other award winners and finalists."

About the Governor's Celebration of Innovation

The Governor's Celebration of Innovation was established in 2003 by combining two technology award ceremonies: the High Tech Industry Cluster's 17-year Innovator of the Year awards ceremony and the Arizona Software and Internet Association's 10-year "Celebration of Innovation." With the addition of the Governor's support, the Governor's Celebration of Innovation has become the premier technology community gathering of its kind in Arizona.

About the Arizona Technology Council

The Arizona Technology Council is a private, not-for-profit trade association founded to connect, represent and support the state's expanding technology industry. To promote economic growth and professional development in Arizona's technology sector, the Council provides members networking opportunities, business support and access to educational forums. The Council strives to distinguish Arizona as a leader in the technology community and offer resources that are exclusive to its members. For more information, please visit http://www.aztechcouncil.org/.

About InNexus

InNexus is a drug development company commercializing the next generation of monoclonal antibodies based on its DXL technology, which improves the potency of existing antibody products while opening new markets and disease applications. DXL antibodies utilize unique, novel and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own in-house developmental facilities. These development resources provide validation of protein and peptide discoveries, enabling InNexus (and its strategic partners) to advance novel drug therapeutics and diagnostics. To learn more about InNexus, please visit http://www.ixsbio.com/.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. This news release may contain assumptions, estimates, and other forward-looking statements that involve inherent risks and uncertainties and are subject to factors, many of which are beyond the Company's control, which may cause actual results or performance to differ materially from those currently anticipated in such statements. 

DATASOURCE: InNexus Biotechnology Inc.



CONTACT: Jeff Morhet, Chairman and Chief Executive Officer of InNexus

Biotechnology Inc., [phone] 



Web site:  http://www.ixsbio.com/

Copyright